小儿哮喘性支气管炎的临床治疗

目的:探讨小儿哮喘性支气管炎的临床治疗措施。方法:选取诊断为小儿哮喘性支气管炎的患儿80例,随机分为A、B两组,每组40例,A组患儿均给予抗感染、化痰止咳等对症治疗;B组在对症治疗的基础上给予雾化吸入普米克、万托林治疗,7d为1个疗程,比较两组的治疗效果。结果:A组16例患儿基本治愈,治愈率为40%,总有效率为77.5%;B组23例患儿基本治愈,治愈率为57.5%,总有效率为95%,两组患儿治愈率、总有效率间差异有统计学意义(P<0.05)。B组患儿临床症状恢复时间短于A组患儿,两组间差异有统计学意义(P<0.05)。结论:常规疗法结合雾化吸入普米克、万托林治疗小儿哮喘性支气管炎临床疗效较好。     

Increased frequency of HLA-B44 in recurrent sinopulmonary infections (RESPI)

To test whether MHC alleles associated with common variable immune deficiency (CVID) might also be over-represented in patients with normal serum immunoglobulin levels who suffer with recurrent sinopulmonary infections (RESPI), we identified 62 consecutive RESPI patients and compared their HLA-B and HLA-DR antigen frequencies to those of 60 consecutive patients with CVID, 1627 Alabama Caucasian bone marrow donors, and 997,230 published US Caucasians. Either HLA-B44, -B8, -DR3(17), or -DR7 was present in 74% of the RESPI and 85% of the CVID patients. HLA-B44 prevalence in particular proved identical between RESPI and CVID. When compared to US Caucasians, the increased prevalence of the four HLA alleles proved significant at P < 0.0001, P < 0.0001, P = 0.0005, and P = 0.02, respectively. When compared to Alabama Caucasians, only the increased prevalence of HLA-B44 achieved statistical significance (P = 0.0001). Inheritance of HLA-B44 may yield susceptibility to recurrent sinopulmonary infection even in the presence of normal serum immunoglobulin levels.     

穴位注射治疗痰湿蕴肺型慢性支气管炎疗效观察

目的观察核酪穴位注射治疗痰湿蕴肺型慢性支气管炎的临床疗效。方法采用随机对照的方法,将103例患者分为治疗组和对照组,治疗组采用核酪穴位注射疗法,对照组采用口服盐酸氨溴索治疗。疗程结束后进行症状评分、生活质量评分。结果两组患者治疗后症状均有改善。治疗组患者的生活质量明显改善,治疗组总有效率优于对照组（P〈0.05）。结论 核酪穴位注射治疗痰湿蕴肺型慢性支气管炎疗效确切,优于单纯西药治疗,同时可以改善患者生活质量。     

四子散热敷治疗慢性支气管炎疗效观察

目的观察四子散热敷治疗慢性支气管炎的临床疗效。方法56例入选患者随机分为治疗组和对照组,对照组26例采用西药抗炎止咳化痰等治疗,治疗组30例在西药治疗的基础上加用四子散（白芥子、苏子、莱服子、吴茱萸）热敷双肺俞。结果治疗组愈显率为96．7％,明显高于对照组的84．6％;治疗组达到显效的平均治疗时间（11．4±4．16）d,明显小于对照组（21．4±4．72）d（P〈O．05）。结论四子散热敷双肺俞能够有效的治疗慢性支气管炎,能够有效地提高疗效,并缩短治疗时间。     

芩胆咳喘康治疗急性支气管炎临床研究

目的 观察芩胆咳喘康片对急性支气管炎的临床疗效。方法 治疗组应用芩胆咳喘康治疗急性支气管炎100例,并与用头孢氨苄胶囊、复方甘草合剂治疗者60例作对照观察。结果 治愈率及总有效率方面,治疗组分别为81％、95％,对照组为51．67％、85％,2组比较有显著性差异（P＜0．01或＜0．05）;2组治疗前后病情积分及主要症状起效时间方面,治疗组均优于对照组（P＜0．01或＜0．05）;治疗组中医药证类疗效比较,风热证优于风寒证及风燥证（P＜0．01）。结论 芩胆咳喘康治疗风热证急性支气管炎安全有效。     

DNA图像分析技术在肺良恶性病变诊断中的价值

目的：研究支气管肺良恶性病变中DNA倍体及DNA指数（D1）情况,评估其在支气管肺良恶性病变诊断中的价值。方法：用图像分析系统（MPIAS－500）对39例支气管粘膜慢性炎症,45例鳞状上皮化生、45例异型增生、63例癌进行DNA倍体分布及DNA指数的检测。结果：支气管粘膜慢性炎症组、鳞状上皮化生组非整倍体均＜1．3％,DI均值分别为0．92和1．03;异型增生组非整倍体为2．8％,DI均值为1．34;而癌症组非整倍体为18．93％;DI均值为1．72,明显高于良性病变组（P＜0．001）。结论：支气管肺良恶性病变细胞核DNA倍体及非整倍体所占的百分比不同。定量分析检测细胞核DNA倍体及DI均值有助于支气管肺良恶性病变的诊断及鉴别诊断,并可为临床治疗和预后判断提供有效的客观指标。     

“冬病夏治”治疗脾肾阳虚型COPD患者36例疗效观察

目的:观察"冬病夏治"治疗脾肾阳虚型COPD患者的疗效。方法:纳入72例患者,随机分为治疗组36例(采用西医常规治疗+冬病夏治)和对照组36例(采用西医常规治疗法),冬病夏治疗程6周,随访观察6个月。结果:两组治疗后中医证候积分与治疗前比较,差异有显著性或非常显著性意义(P<0.05,P<0.01),治疗组中医证候改善明显优于对照组;总有效率治疗组为88.89%,对照组为63.89%,两组差异有显著性意义(P<0.05);对照组FEV1%、FEV1/FVC治疗前后比较,差异均有显著性意义(P<0.05);治疗后FEV1%、FEV1/FVC,治疗组与对照组比较,差异均有显著性意义(P<0.01);治疗组急性发作次数治疗组明显少于对照组(P<0.01),最长持续时间治疗组明显少于对照组(P<0.05),平均住院天数、次数治疗组均优于对照组(P<0.05)。结论:结合"冬病夏治"治疗脾肾阳虚型COPD患者疗效较好,该法具有中医特色,临床开展简、便、廉、捷,值得临床推广。     

A detailed biochemical characterization,toxicological assessment and molecular docking studies of Launaea fragilis: An important medicinal xero-halophyte

Launaea fragilis (Asso) Pau (Family: Asteraceae) is a wild medicinal plant that has been used in the folklore as a potential treatment for numerous ailments such as skin diseases, diarrhea, infected wounds, inflammation, child fever and hepatic pain. This study explored the chemical constitution, in-vivo toxicity, antimicrobial, antioxidant, and enzyme inhibition potential of ethanolic extract of L. fragilis (EELF). Additionally, in-silico docking studies of predominant compounds were performed against in-vitro tested enzymes. Similarly, in-silico ADMET properties of the compounds were performed to determine their pharmacokinetics, physicochemical properties, and toxicity profiles. The EELF was found rich in TFC (73.45 ± 0.25 mg QE/g) and TPC (109.02 ± 0.23 mg GAE/g). GC–MS profiling of EELF indicated the presence of a total of 47 compounds mainly fatty acids and essential oil. EELF showed no toxicity or growth retardation in chicks up to 300 mg/kg with no effect on the biochemistry and hematology of the chicks. EELF gave promising antioxidant activity through the CUPRAC method with an IC₅₀ value of 13.14 ± 0.18 µg/ml. The highest inhibition activity against tyrosinase followed by acetylcholinesterase and α-Glucosidase was detected. Similarly, the antimicrobial study revealed the extract with good antibacterial and antiviral activity. A good docking score was observed in the in silico computational study of the predominant compounds. The findings revealed L. fragilis as a biocompatible, potent therapeutic alternative and suggest isolation and further in vivo pharmacological studies.